Evidence map›Paper›PMID 41107292›Full record

ArticleScientific reports2025

Comparative evaluation of amiodarone and furosemide compatibility under different mixing conditions.

So Iwabuchi, Toru Imai, Naoto Suzuki, Hiroshi Nango, Taiki Nagatomo, Hiroko Miyagishi, Toyofumi Suzuki, Susumu Ootsuka, Yasuhiro Kosuge

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

So Iwabuchi *School of Pharmacy Laboratory of Pharmacology , Nihon University , Chiba, Japan.
Toru Imai *Department of Pharmacy , Nihon University Itabashi Hospital , Tokyo, Japan.
Naoto SuzukiSchool of Pharmacy Laboratory of Pharmaceutics , Nihon University , Chiba, Japan.
Hiroshi NangoSchool of Pharmacy Laboratory of Pharmacology , Nihon University , Chiba, Japan.
Taiki NagatomoSchool of Pharmacy Laboratory of Pharmaceutics , Nihon University , Chiba, Japan.
Hiroko MiyagishiSchool of Pharmacy Laboratory of Pharmacology , Nihon University , Chiba, Japan.
Toyofumi SuzukiSchool of Pharmacy Laboratory of Pharmaceutics , Nihon University , Chiba, Japan.
Susumu OotsukaDepartment of Pharmacy , Nihon University Hospital , Tokyo, Japan.
Yasuhiro KosugeSchool of Pharmacy Laboratory of Pharmacology , Nihon University , Chiba, Japan. kosuge.yasuhiro@nihon-u.ac.jp.

Funding

Japan Society for the Promotion of Science 23K14395Nihon University Multidisciplinary Research Grant for 2022-2023 #22Dokusen11
6 · The paper itself

Abstract

Amiodarone and furosemide are frequently administered together in the intensive care unit, and their co-administration poses a risk of precipitation and catheter occlusion due to incompatibility. Thus, compatibility should be evaluated under clinically relevant conditions to ensure safe drug administration. This study investigated the impact of different mixing procedures on the physical compatibility of amiodarone and furosemide by employing two clinically relevant approaches: simulated mixing (SM) and route mixing (RM). Mixtures were prepared at therapeutic concentrations and evaluated by visual inspection, absorbance measurement, powder X-ray diffraction (PXRD), pH analysis, and particle size assessment. Although the drug ratios were identical, the RM samples displayed greater turbidity than the SM samples. The PXRD analysis showed no formation of new crystalline substances, and the precipitates consisted of known furosemide and amiodarone hydrochloride polymorphs. The pH shifted toward the alkaline range as the injection volume increased with furosemide dose. Importantly, differences in particle growth behavior were noted between SM and RM, with larger particles observed in the RM samples. In conclusion, mixing route significantly affects drug compatibility, with RM presenting a higher risk of precipitation. Assessing drug compatibility under clinically relevant conditions may help prevent catheter-related complications and improve the safety of intravenous pharmacotherapy.

Indexed as

AmiodaroneFurosemideDrug IncompatibilityHydrogen-Ion ConcentrationParticle SizeX-Ray DiffractionAmiodaroneFurosemideAmiodaroneFurosemideIntensive care unitMedication safetyMixingPhysical compatibility

Identifiers

PMID41107292
PMCPMC12534369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.